Prosecution Insights
Last updated: April 19, 2026

BIOMARIN PHARMACEUTICAL INC.

7 pending office actions

Portfolio Summary

7
Total Pending OAs
1
Final Rejections
6
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18573298 COMPOSITIONS OF BETA-HEXOSAMINIDASE VARIANTS AND USES THEREOF SWIFT, CANDICE LEE 1657 Non-Final OA Dec 21, 2023
18273430 AAV PRODUCTION SYSTEMS FOR AAV VIRAL PARTICLES WITH IMPROVED INFECTIVITY PENNINGTON, HALLIE NICOLE 1671 Non-Final OA Jul 20, 2023
18311789 METHOD OF TREATING DUCHENNE MUSCULAR DYSTROPHY MEYERING, SHABANA SHABBEER 1635 Non-Final OA May 03, 2023
18192480 DYSTROPHIN EXON SKIPPING OLIGONUCLEOTIDES TRAN, CHRISTINA L 1637 Non-Final OA Mar 29, 2023
17815468 Lysosomal Targeting Peptides and Uses Thereof ALLEN, MARIANNE P 1647 Non-Final OA Jul 27, 2022
17829620 Lysosomal Targeting Peptides and Uses Thereof ALLEN, MARIANNE P 1647 Non-Final OA Jun 01, 2022
17073828 Variants of C-Type Natriuretic Peptide DRISCOLL, LORA E BARNHART 3991 Final Rejection Feb 22, 2021

Managing BIOMARIN PHARMACEUTICAL INC.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month